Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post Marketing Surveillance Study of the Labeled Use of Remicade® (Infliximab) in Patients With Chronic Inflammatory Diseases

NCT00727298 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.

NCT NCT00727298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00727298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post Marketing Surveillance Study of the Labeled Use of Remicade® (Infliximab) in Patients With Chronic Inflammatory Diseases
Lead sponsor
Merck Sharp & Dohme LLC
Phase
Observational
Overall status
Completed
Start date
February 28, 2006
Completion date
August 31, 2011
Enrollment
4,485 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, psoriatic, arthritis, rheumatoid, crohn's disease, psoriasis, spondylitis, ankylosing